Previous close | 0.6700 |
Open | 0.6700 |
Bid | 0.0000 |
Ask | 0.7500 |
Strike | 1.50 |
Expiry date | 2025-01-17 |
Day's range | 0.6700 - 0.6700 |
Contract range | N/A |
Volume | |
Open interest | 424 |
2Flo Ventures, an emerging venture capital firm and startup studio focused on the discovery, development, and commercialization of healthcare solutions that address disparities in outcomes and health equity broadly, is pleased to announce the addition of Dr. Charlotte Jones-Burton as a Partner and Head of Life Science Product Development and Strategy.
SOMERVILLE, Mass., May 29, 2024--bluebird bio, Inc. (Nasdaq: BLUE) today announced that O. James Sterling, has been appointed chief financial officer (CFO), effective June 10, 2024. Mr. Sterling most recently served as chief financial officer of Renalytix plc, a diagnostics company focused on clinical management of kidney disease.
Detailed Analysis of Financial Performance and Future Outlook